(Cisplatin + vinblastine sulphate) is under clinical development by Intensity Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect (Cisplatin + vinblastine sulphate)’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Cisplatin + vinblastine sulphate) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
(Cisplatin + vinblastine sulphate) overview
Cisplatin in a fixed dose combination with vinblastine sulfate (INT-2306) is under development for the treatment of solid tumors, melanoma, lymphoma, head and neck, liver, chordoma, metastatic colorectal cancer, cutaneous squamous cell carcinoma, lung, metastatic pancreatic, ovarian, thyroid, colon, metastatic hepatocellular carcinoma, triple negative breast cancer, breast cancer, soft tissue sarcomas, glioblastoma multiforme and bile duct cancer. The drug candidate is administered intratumorally and intravenously. The drug candidate is developed based on intratumoral amphiphilic solutions technology.
Intensity Therapeutics overview
Intensity Therapeutics is a clinical-stage biotechnology company that focuses on human clinical testing to treat refractory solid tumor cancers. The company is headquartered in Fairfield, Connecticut, the US.
Quick View (Cisplatin + vinblastine sulphate) LOA Data
|Highest Development Stage|